Laddar populära aktier...
The Q2 report showed that Covid-19 is still challenging for Bactiguard, although it showed signs of stabilisation in BD licence revenues.
Bactiguard’s Q2 sales of SEK 46m were in line with our expectations, however, excluding a milestone payment from Zimmer Biomet (SEK 8.
